Single vialReady To Order
Retatrutide
Two vial sizes. Seven kit options.
Choose 10 mg or 30 mg vials, or a 10-vial kit. Find your format below and explore the published research.
For laboratory research use only. Not for human consumption, medical, or veterinary use.
Choose your Retatrutide.
Two single-vial sizes. Seven kit strengths. Select your format and add it directly to your cart.
Single vialReady To Order
10-vial kitReady To Order
Clear quantitiesStrengths are amounts per vial. Each kit contains 10 vials.
Shipping & fulfillmentReview shipping options and timing
Questions before ordering?Ask our team about your selection
See the Janoshik report.
Review the original Janoshik report for the tested Method Peptides 10 mg sample, including measured content, purity, and verification details.
- Reported purity
- 99.121%
- Measured Retatrutide
- 10.27 mg
Verify with JanoshikUnique key: 71BM98RRNQKF
Open full-size test report
Explore the weight-loss studies.
Retatrutide is studied for activity at GLP-1, GIP, and glucagon receptors. Start with these peer-reviewed obesity trials.
These trials studied investigational retatrutide under controlled clinical conditions. They did not test Method Peptides products, and their findings do not establish the safety, effectiveness, or appropriate human use of the materials sold here.
48-week obesity trial
In a randomized trial of 338 adults, the 12 mg study arm had a 24.2% least-squares mean reduction in body weight at 48 weeks, compared with 2.1% for placebo. The study’s primary endpoint was measured at 24 weeks; the 48-week result was a secondary endpoint.
Gastrointestinal adverse events were common, and dose-dependent increases in heart rate were observed. Study-arm amounts describe the trial, not product-use instructions. Funded by Eli Lilly.
Read the study on PubMed80-week obesity trial
TRIUMPH-1 randomized 2,339 adults with obesity without diabetes. At 80 weeks, the reported mean body-weight change was −25.0% in the 12 mg arm and −3.9% with placebo, using a treatment-regimen (intention-to-treat) estimand.
Gastrointestinal events were the most common adverse events. Population, trial duration, and analysis differ from the phase 2 trial; these results should not be compared as equivalent estimates. Funded by Eli Lilly.
Read the study on PubMedA few useful details.
Product formats and research-use information.
What is the difference between a vial and a kit?
A single-vial selection contains one vial at the chosen amount: 10 mg or 30 mg. A kit contains 10 vials, all at the strength you select. For example, a 10 mg kit contains 10 × 10 mg vials, for 100 mg total.
Which strengths are available in kits?
The kit range includes 5, 10, 15, 20, 30, 40, and 50 mg per vial. Every kit contains 10 vials. Select a strength above to see its current kit price and per-vial price.
Are these products intended for human use?
No. These materials are supplied for laboratory research only and are not for human consumption, medical, or veterinary use. Clinical publications are provided as scientific references, not as instructions for using these products.
Find your research format.
10 mg and 30 mg single vials. Seven strengths of 10-vial kits.